Today: 9 June 2026
Synopsys stock climbs as CES automotive push and chip rally lift SNPS shares
6 January 2026
1 min read

Synopsys stock climbs as CES automotive push and chip rally lift SNPS shares

New York, Jan 6, 2026, 15:51 EST — Regular session

  • Synopsys shares rise about 3% in afternoon trading as chip stocks gain
  • Company highlights new automotive engineering partnerships and virtual testing tools at CES 2026
  • Investors watch CEO comments at CES on Jan. 7 and the next earnings date listed by market calendars

Shares of Synopsys Inc rose 2.9% to $508.47 in afternoon trading on Tuesday, extending gains from the prior session. The stock has traded between $494.19 and $509.40, with about 1.4 million shares changing hands.

The move matters because electronic design automation — software used to design and test chips — often moves early in the spending cycle, when customers lock in tools ahead of new silicon projects. Synopsys is also trying to deepen its foothold in automotive engineering as carmakers add more computing power and sensors.

The PHLX semiconductor index was up 2.7% on Tuesday on renewed AI optimism, Reuters reported. “We’re going to have a very strong earnings season for Big Tech,” said Jed Ellerbroek, a portfolio manager at Argent Capital. Investors are also watching Wednesday’s JOLTS labor report and Friday’s U.S. jobs data for clues on interest rates.

Synopsys said its Ansys AVxcelerate Sensors product now includes Samsung Electronics’ ISOCELL Auto 1H1 image sensor to help teams simulate and test systems before hardware is built, and that it will support the Fédération Internationale de l’Automobile on single-seater safety standards. The company also announced new “virtual development kits” — software models that let engineers build and test a system-on-chip in software — with partners including NXP Semiconductors, Texas Instruments and Arm. Chief product management officer Ravi Subramanian said software-defined mobility “necessitate a foundational shift” in automotive engineering. Synopsys Investor Relations

Rival Cadence Design Systems rose 4.5% to $314.87. Synopsys competes in electronic design automation with Cadence and Siemens.

A Form 4, a required disclosure of insider trades, showed Synopsys general counsel and corporate secretary Janet Lee received 130 shares from vested restricted stock units. The filing said 49 shares were withheld to cover taxes at a price of $469.72 on Dec. 31.

In December, Synopsys projected fiscal 2026 revenue of $9.57 billion to $9.65 billion and adjusted profit of $14.32 to $14.40 per share, including about $2.9 billion of expected Ansys revenue. It ended fiscal 2025 with $11.4 billion in backlog, the company said. The stock is about 22% below its 52-week high of $651.73 and trades at about 62 times trailing earnings, according to SoFi.

But the shares have been sensitive to any hint that customers are delaying chip projects, since design starts can slow quickly when budgets tighten. Automotive programs add another moving part, as car demand and regulation can change the pace of development.

Investors will next listen for comments from CEO Sassine Ghazi, who is scheduled to appear at CES on Wednesday, Jan. 7, in a session hosted by Six Five Media. Market calendars list Synopsys’ next earnings date as Feb. 25, though the company has not confirmed it.

Stock Market Today

  • SailPoint Q1 Earnings Beat Estimates Amid Revenue Growth
    June 9, 2026, 10:14 AM EDT. SailPoint, Inc. (SAIL) reported Q1 earnings of $0.05 per share, surpassing the Zacks Consensus Estimate of $0.04 by 17.65%. Revenue increased to $280.14 million, beating estimates by 1.41% and up from $230.47 million a year ago. Despite earnings surprises and revenue growth, SailPoint shares have declined 12.6% year-to-date against the S&P 500's 8.2% rise. The company holds a Zacks Rank #3 (Hold), indicating expected market-aligned performance. Consensus estimates forecast Q2 EPS of $0.08 on $310.79 million revenue and fiscal year EPS of $0.32 on $1.27 billion revenue. Industry trends in the Zacks Internet-Software sector will influence future stock performance. Investors await management's commentary for guidance on sustainability.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Merck stock hits 52-week high as vaccine policy shift and JPM conference loom
Previous Story

Merck stock hits 52-week high as vaccine policy shift and JPM conference loom

Western Digital (WDC) stock jumps 17% after Nvidia CES storage talk sparks AI-driven rally
Next Story

Western Digital (WDC) stock jumps 17% after Nvidia CES storage talk sparks AI-driven rally

Go toTop